Skip to content
Company Analysis

Neogen Corporation NEOG

A comprehensive view of key metrics, scores, and financial health for Neogen Corporation

Overview of Neogen Corporation

NEOG NMS
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics Mid Cap
Neogen Corporation (NEOG), is a Mid Cap company, in the Diagnostics & Research industry, last closed at $12.21, about 50.6% overvalued vs fair value, +98.2% 1Y return, ranked 398/1145 in sector.
Metrics Rev Growth -2.7% ROE -0.4% Gross Margin 46.9%
USD 12.21
0.16%
(Delayed)
• Vol 90d: 53.6%
52-Week Range
Market Cap
$2.67B
Enterprise Value
$3.27B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 88%
Confidence: 90%
Updated: Oct 24
Top Beats

Quick Facts

Website https://www.neogen.com
HQ Lansing, MI
Employees 2,974
Fiscal year May 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$5
$6
$7
Current: $12.21 -51% vs base

Engine Room Money Flow™

Mid Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$870.4M
-2.7%%
Gross Profit
$408.5M
-3.1%%
Operating Income (GAAP)
-$21.6M
98%%
EBITDA
$170.5M
118.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
46.9%
Fair

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
5
Active Leaks
4/5
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Neogen Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
55
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Stable Gross Margin Profile Gross margin stability is strong (score 0.78). Low volatility confirms durable consumable pricing.
  • Above-Peer Asset Productivity Asset productivity is strong vs peers (score 0.70). Above-peer ROA underpins the growth durability narrative.

Key risks

  • Operating Margin Compression Operating margin trend is negative (score 0.16). Sustained compression would reduce the commercial moat.
  • Elevated Leverage Leverage is elevated vs peers (score 0.34). High net debt/EBITDA limits the balance sheet's acquisition firepower.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
61
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing NEOG's balance between Growth (29.9%), Profitability (38.0%), and Safety (32.1%). Growth 30% Safety 32% Profitability 38%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

47th percentile vs peers
47
Key Signals
EPS Growth YoY 99.3% 88p Rev Growth YoY -2.7% 27p Revenue CAGR 3Y 1.9% 36p Asset Growth YoY -2.8% 40p
Strengths
  • EPS Growth YoY in top 20% of peers (99.3%, 88th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • Consistently strong margins across 3 metrics
Risks

No significant risks identified for this axis.

Profitability

59th percentile vs peers
60
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

50th percentile vs peers
50
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Neogen Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$6.03
- - -
-50.6% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000